close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Safety Profile

Although the safety of viscosupplementation has been well documented, your patients may have questions about the incidence of local adverse effects. The results below should help you address any concerns.

In one of the largest viscosupplement studies ever conducted to evaluate the safety profile of SYNVISC® in standard clinical practice,1 the majority (95.8%) of SYNVISC patients were free of treatment-related adverse effects. Adverse effects, when they occurred, were easily managed, and did not interfere with the benefits of SYNVISC therapy. 1, 2, 3

SYNVISC demonstrates a low incidence of treatment-related adverse events

SYNVISC patients free of local adverse events1

Prospective, observational study of 4,253 patients with OA knee pain to evaluate the short-term tolerability and effectiveness of SYNVISC in standard clinical practice.

Additionally in clinical trials knee pain/swelling occurred in 2.2% of first course treatment injections and 7.2% of patients.

View the Complete Prescribing Information for SYNVISC (PDF, 146K) for full details.

Local adverse events with SYNVISC are generally mild to moderate, easily managed, and do not preclude clinical benefit. 1, 2, 3




Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)